CD19 negative and dim precursor B-lineage acute lymphoblastic leukemias: real-world challenges in a targeted-immunotherapy era
| Autor: | Tenali Gnana Sagar, Jhansi Rani Arumugam, Priya T Rajan, B K Karthik Bommannan, Shirley Sundersingh, Venkatraman Radhakrishnan |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Lineage (genetic) Neoplasm Residual Adolescent Lymphoblastic Leukemia Antigens CD19 chemical and pharmacologic phenomena Cell Separation Targeted immunotherapy Cohort Studies 03 medical and health sciences Young Adult 0302 clinical medicine Antineoplastic Agents Immunological immune system diseases hemic and lymphatic diseases Internal medicine Precursor B-Cell Lymphoblastic Leukemia-Lymphoma medicine Humans Child B-Lymphocytes business.industry hemic and immune systems Hematology Flow Cytometry Minimal residual disease 030220 oncology & carcinogenesis Child Preschool Acute lymphoblastic leukemias Female CD19 Negative Neoplasm Recurrence Local business 030215 immunology |
| Zdroj: | Leukemialymphoma. 60(13) |
| ISSN: | 1029-2403 |
| Popis: | Flow cytometric diagnosis and minimal residual disease (MRD) assessment of precursor B-lineage acute lymphoblastic leukemia (B-ALL) are heavily dependent on CD19 based gating strategies. However, this approach is not optimal in the diagnosis and follow-up of CD19 negative or dim B-ALLs. Though CD19 negative B-ALLs are rare, in the current era of CD19 targeted immuno-therapy, CD19 negative B-ALL relapses are frequent. We have presented our cohort of 14 de novo CD19 negative and dim B-ALLs and have highlighted the difficulties faced during diagnosis and MRD assessment of these patients. We have also discussed the need to identify alternative B-lineage gating markers and strategies to deal with such scenarios. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |